2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Bioinformatics, Clinical Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Study Population, Human, Adult
PAPER

5720 Mass spectrometry–based screening reveals frequent monoclonal gammopathies, including clinically relevant MGUS and SMM, in first-degree relatives of patients with multiple myeloma or lymphoma: The israeli promise cohort

Irit Avivi, MD, Sabine Allam, MD2, Joseph Flinn3, Katherine Padgett, MS4, Jacqueline Perry, MPH5, Julia Colchie, BA, MA6, Iuliana Vaxman, MD, BA7, Dana Gamzu8, Ori Grossberger, MD9, Ella Krayzler10, Ruth Greenwald11, Tamir Shragai, MD12, Yael C. Cohen, MD13, Irene M Ghobrial, MD14
1 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Hematology department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
2 Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
3 The Binding Site, a part of ThermoFisher Scientific, Waltham, Massachusetts, United States
4 Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
5 Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
6 Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
7 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, The Binding Site, a part of ThermoFisher Scientific, Waltham, Massachusetts, United States
8 Hematology department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
9 Hematology department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
10 Hematology department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
11 Hematology department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
13 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Hematology department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
14 Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Background: Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). First-degree relatives (FDRs) of patients with plasma-cell or lymphoid malignancies carry an increased risk of monoclonal gammopathy. Mass spectrometry (MS) is more sensitive than serum protein electrophoresis (SPEP)/immunofixation (IFE) and can detect even very low-level clones, termed monoclonal gammopathy of indeterminate potential (MGIP), that conventional assays miss. Leveraging the PROMISE international framework (NCT03689595), we sought to define the prevalence, isotype distribution, and clinical correlates of MS-defined MGUS and MGIP among Israeli FDRs, to establish the added value of MS over conventional serology, and to benchmark our results against the published PROMISE cohort (El-Khoury et al., Lancet Haematol 2022).

Methods: FDRs of patients with MM or lymphoma, age ≥ 30 years, with no known MGUS, prior B cell lymphoma or autoimmune disorder, were invited to participate in the Israeli branch of  PROMISE. FDRs were prospectively screened for MGUS at two medical centers (Tel Aviv Sourasky/Ichilov; Rabin Medical Center). A comparison group without an affected FDR was screened in parallel. Sera were analyzed at Dana-Farber by MALDI-TOF MS and were also assessed by the conventional MM profile (IFE, SPEP, and serum free light chains).Individuals were categorized as MS MGUS if they had either (i) a heavy chain peak ≥0.2 g/L, (ii) an abnormal FLC ratio, or (iii) light chain MGUS (LC-MGUS), or as MGIP (<0.2 g/L).SMM was defined if bone marrow aspirate/ biopsy, performed upon clinical decision, demonstrated >=10% clonal plasma cells (- in the absence of end-organ damage or SLIM CRAB). The FDRs and the Controls were compared by Mann-Whitney and chi-square tests.

Results: Analysis using MS and conventional multiple myeloma (MM) profiling were performed in 316 individuals, while 28 were evaluated via conventional profiling alone. Among the entire cohort of 344 first-degree relatives (FDRs) studied (median age: 51 years; 203 women), monoclonal protein was detected in 120 participants (34.9%). Monoclonal gammopathy of undetermined significance (MGUS) was present in 40 participants (11.6%);19 determined as conventional and MS-MGUS, 17 MS-MGUS only, and 4 LC-MGUS; 5 met SMM criteria on marrow (15-30% clonal plasma cells, 4 high-risk). MGIP without accompanying MGUS occurred in 80 of 316 MS-tested subjects (25.3%). MGUS-spectrum clones were predominantly IgG (26/40), whereas MGIP was predominantly IgM (60/80); notably, 26 of 40 MS-MGUS subjects (65%) harbored a concurrent MGIP-level clone, most often IgM. Median MS monoclonal concentration in MS-MGUS-spectrum was 0.42 g/L and median FLC ratio 1.30 (range 0.79-100.9).

Older age was the only statistically significant correlate of any monoclonal finding (median 53 vs 49 years; p=0.008) and of MGUS-spectrum disease (p=0.011); sex, relationship type, the relative's malignancy; MM vs NHL, and number of affected relatives were not statistically significant, with a non-significant trend among siblings (p=0.055). Benchmarked against PROMISE published data at age >=50, matched Israeli rates closely replicated the published cohort: any monoclonal protein; 41.9% (78/186) vs ~43%, MS-MGUS 15.1% (28/186) vs 13%, and MGIP 26.9% (50/186) vs ~28-30%, with the same age gradient (MS-MGUS 7.6% at <50 and 16.0% at >=70), male predominance of MS-MGUS (18.1% vs 13.2%), and IgM-predominant MGIP. In the comparison group (n=35; median 59 years) any monoclonal protein reached 45.7% and MGIP 40.0%, but MGUS-spectrum disease was only 5.7%.

Conclusions: MS-based screening detected a monoclonal protein in ~one-third of FDRs of patients with MM or lymphoma, whereas conventional serology confirmed MGUS in only 47.5% of MS-diagnosed cases, indicating that routine tests substantially underestimates precursor disease, which MS reveals. Screening was clinically actionable: 5 FDRs had incidental SMM (4 high-risk). MGUS-spectrum disease, the finding most specific to inherited risk, was about twice as frequent as in controls (11.6% vs 5.7%). Age-matched rates closely reproduced PROMISE despite a family-history-only design, supporting a genuine familial predisposition to clinically relevant precursor states, whereas low-level, IgM-predominant MGIP was common in both groups and higher in older controls, indicating a largely age-driven, non-specific phenomenon.
Irit Avivi, MD: Roche - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)